KUMHO HT Swings to Net Profit of 3.8B Won in Q1 2026, Pursues Share Consolidation and Capital Reduction
Consolidated Q1 2026 revenue 85.3B won (down 17% YoY), operating profit 1.6B won (down 38% YoY), net profit 3.8B won (up 142% YoY), turning to black.
Planned: 10:1 share split in April 2026, cancellation of 890,792 treasury shares in May (capital decrease of 4.5B won), 50% capital reduction in June (2:1 reverse split, capital decrease of 52.3B won).
Consolidated debt-to-equity ratio 35.9%, net debt 6.8B won (vs net cash 17B at year-end 2025), cash equivalents 35.6B won.
Bio pipeline: DNP002 (CEACAM6) Phase 1 completed, DNP007 (ICAM-1) investigator-initiated Phase 1 completed, DNP005 (CD40) in non-clinical development.
Credit ratings maintained: BB+ (NICE D&B) to BBB (Korea Ratings).